Howe Jill Ann

CFO Jill Ann Howe buys 15,000 LCTX shares at $0.59; stock down -59.5% from 52-week high, company unprofitable.

CFO Jill Ann Howe purchased 15,000 shares at $0.59 on 2024-11-26, increasing her holdings by 142.9% to 25,500 shares total. This buy occurs amid significant price weakness: the stock trades at $0.60, down -59.5% from its 52-week high and -28.7% over the prior 30 days. The company reported negative net income of $-3,034,000.00 in the latest quarter and is unprofitable on a full-year basis, with annual revenue declining -39.2% year-over-year. Notably, a cluster of 3 other insiders also purchased within the past 14 days, and Howe's prior open-market buy at this same ticker (2024-08-16) showed a -0.6% 90-day return—a pattern of poor timing on her past trades. The combination of accelerating losses, revenue contraction, depressed valuation, and an insider track record showing 0% win rate on 90-day holds raises material questions about the sustainability of the current operations.

CFO Jill Ann Howe purchases 10,500 shares of LCTX at $0.89 amid -39.2% annual revenue decline and $-5.8M net loss.

CFO Jill Ann Howe purchased 10,500 shares (10.5K shares) at $0.89 on 2024-08-16, establishing an initial position in Lineage Cell Therapeutics. This purchase occurred in a deteriorating financial environment: the company reported annual revenue growth of -39.2%, generated a net loss of $-5.8M on quarterly revenue of $1.4M, and the stock has declined -40.5% from its 52-week high of $1.48. At $0.88 current price, the transaction is underwater by approximately -1% relative to the purchase price. The buy coincides with significant operational challenges and negative momentum, warranting closer examination of whether this reflects management's assessment of valuation or other strategic considerations.